Top

Journal of Autism and Developmental Disorders

Gepubliceerd in:

16-05-2015 | Letter to the Editor

Reduction of Aggressive Episodes After Repeated Transdermal Nicotine Administration in a Hospitalized Adolescent with Autism Spectrum Disorder

Auteurs: Gerrit I. Van Schalkwyk, Alan S. Lewis, Zheala Qayyum, Kourtney Koslosky, Marina R. Picciotto, Fred R. Volkmar

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 9/2015

Abstract

Aggression remains a major cause of morbidity in patients with autism spectrum disorder (ASD). Current pharmacotherapy for aggression is not always effective and is often associated with morbidity. Nicotinic acetylcholinergic neurotransmission may play a prominent role in ASD pathophysiology based on human and animal studies, and preclinical studies show nicotine administration can reduce aggression-related behaviors. Transdermal nicotine has been used to treat agitation in neuropsychiatric conditions with cholinergic dysfunction. Here we report the use of transdermal nicotine as an adjunctive medication to treat aggression in a hospitalized adolescent with ASD. Nicotine patch was recurrently well tolerated, and reduced the need for emergency medication and restraint. These findings suggest further study of transdermal nicotine for aggression comorbid with ASD is warranted.

vorige artikel Brief Report: The Association of Autistic Traits and Behavioural Patterns in Adolescents Receiving Special Educational Assistance

volgende artikel Dave Kot and Angela Kot: Face Value Comics, No. 1

Adler, B. A., Wink, L. K., Early, M., Shaffer, R., Minshawi, N., McDougle, C. J., & Erickson, C. A. (2014). Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: A chart review study. Autism: The International Journal of Research and Practice,. doi:10.1177/1362361314524641.

Allen, M. H., Debanné, M., Lazignac, C., Adam, E., Dickinson, L. M., & Damsa, C. (2011). Effect of nicotine replacement therapy on agitation in smokers with schizophrenia: A double-blind, randomized, placebo-controlled study. The American Journal of Psychiatry, 168(4), 395–399. doi:10.1176/appi.ajp.2010.10040569.CrossRefPubMed

Arnold, L. E., Aman, M. G., Hollway, J., Hurt, E., Bates, B., Li, X., et al. (2012). Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology, 22(3), 198–205. doi:10.1089/cap.2011.0056.PubMedCentralCrossRefPubMed

Arnold, L. E., Anand, R., & Aman, M. (2013). Varencline in autistic disorder: Hypothesis and case report of single-patient crossover. Journal of Child and Adolescent Psychopharmacology,. doi:10.1089/cap.2012.0025.

Berntson, G. G., Beattie, M. S., & Walker, J. M. (1976). Effects of nicotinic and muscarinic compounds on biting attack in the cat. Pharmacology, Biochemistry and Behavior, 5(3), 235–239.CrossRefPubMed

Buckley, A. W., Sassower, K., Rodriguez, A. J., Jennison, K., Wingert, K., Buckley, J., et al. (2011). An open label trial of donepezil for enhancement of rapid eye movement sleep in young children with autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology, 21, 353–357. doi:10.1089/cap.2010.0121.PubMedCentralCrossRefPubMed

Carmel, H., & Sheitman, B. B. (2007). Adjunctive transdermal nicotine reduced behavioral agitation in severe dementia. The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry, 15(5), 449. doi:10.1097/01.JGP.0000235688.05709.e2.CrossRef

Deutsch, S. I., Urbano, M. R., Neumann, S. A., Burket, J. A., & Katz, E. (2010). Cholinergic abnormalities in autism: Is there a rationale for selective nicotinic agonist interventions? Clinical Neuropharmacology, 33(3), 114–120. doi:10.1097/WNF.0b013e3181d6f7ad.CrossRefPubMed

Driscoll, P., & Baettig, K. (1981). Selective inhibition by nicotine of shock-induced fighting in the rat. Pharmacology, Biochemistry and Behavior, 14(2), 175–179.CrossRefPubMed

Hajek, P., McRobbie, H., & Gillison, F. (2007). Dependence potential of nicotine replacement treatments: Effects of product type, patient characteristics, and cost to user. Preventive Medicine, 44, 230–234. doi:10.1016/j.ypmed.2006.10.005.CrossRefPubMed

Handen, B. L., Johnson, C. R., McAuliffe-Bellin, S., Murray, P. J., & Hardan, A. Y. (2011). Safety and efficacy of donepezil in children and adolescents with autism: Neuropsychological measures. Journal of Child and Adolescent Psychopharmacology, 21, 43–50. doi:10.1089/cap.2010.0024.PubMedCentralCrossRefPubMed

Hardan, A. Y., & Handen, B. L. (2002). A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 12, 237–241. doi:10.1089/104454602760386923.CrossRefPubMed

Hartley, S., Sikora, D., & McCoy, R. (2008). Prevalence and risk factors of maladaptive behaviour in young children with Autistic Disorder. Journal of Intellectual Disability Research, 52(10), 819–829. doi:10.1111/j.1365-2788.2008.01065.x.Prevalence.PubMedCentralCrossRefPubMed

Hellings, J. A., Zarcone, J. R., Crandall, K., Wallace, D., & Schroeder, S. R. (2001). Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. Journal of Child and Adolescent Psychopharmacology, 11(3), 229–238. doi:10.1089/10445460152595559.CrossRefPubMed

Hoppman-Chaney, N., Wain, K., Seger, P. R., Superneau, D. W., & Hodge, J. C. (2013). Identification of single gene deletions at 15q13.3: Further evidence that CHRNA7 causes the 15q13.3 microdeletion syndrome phenotype. Clinical Genetics, 83, 345–351. doi:10.1111/j.1399-0004.2012.01925.x.CrossRefPubMed

Hughes, J. R., Pillitteri, J. L., Callas, P. W., Callahan, R., & Kenny, M. (2004). Misuse of and dependence on over-the-counter nicotine gum in a volunteer sample. Nicotine and Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco, 6, 79–84. doi:10.1080/14622200310001656894.CrossRef

Johnson, S. K., Carlson, K. M., Lee, J., Burr, L. E., & Wagner, G. C. (2003). Effects of nicotine on target biting and resident-intruder attack. Life Sciences, 73(3), 311–317.CrossRefPubMed

Joseph, A. M., Norman, S. M., Ferry, L. H., Prochazka, A. V., Westman, E. C., Steele, B. G., et al. (1996). The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. The New England Journal of Medicine, 335, 1792–1798. doi:10.1056/NEJM199612123352402.CrossRefPubMed

Kanne, S. M., & Mazurek, M. O. (2011). Aggression in children and adolescents with ASD: Prevalence and risk factors. Journal of Autism and Developmental Disorders, 41(7), 926–937. doi:10.1007/s10803-010-1118-4.CrossRefPubMed

Karvat, G., & Kimchi, T. (2014). Acetylcholine elevation relieves cognitive rigidity and social deficiency in a mouse model of autism. Neuropsychopharmacology, 39, 831–840. doi:10.1038/npp.2013.274.PubMedCentralCrossRefPubMed

Kemper, T. L., & Bauman, M. (1998). Neuropathology of infantile autism. Journal of Neuropathology and Experimental Neurology, 57, 645–652. doi:10.1097/00005072-199807000-00001.CrossRefPubMed

Leblond, C. S., Heinrich, J., Delorme, R., Proepper, C., Betancur, C., Huguet, G., et al. (2012). Genetic and functional analyses of SHANK2 mutations suggest a multiple hit model of autism spectrum disorders. PLoS Genetics, 8(2), e1002521. doi:10.1371/journal.pgen.1002521.PubMedCentralCrossRefPubMed

Lee, M., Martin-Ruiz, C., Graham, A., Court, J., Jaros, E., Perry, R., et al. (2002). Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain: A Journal of Neurology, 125(Pt 7), 1483–1495.CrossRef

Levin, E. D. (2013). Complex relationships of nicotinic receptor actions and cognitive functions. Biochemical Pharmacology,. doi:10.1016/j.bcp.2013.07.021.

Martin-Ruiz, C. M., Lee, M., Perry, R. H., Baumann, M., Court, J. A., & Perry, E. K. (2004). Molecular analysis of nicotinic receptor expression in autism. Brain Research. Molecular Brain Research, 123(1–2), 81–90. doi:10.1016/j.molbrainres.2004.01.003.CrossRefPubMed

McDougle, C. J., Stigler, K. A., & Posey, D. J. (2003). Treatment of aggression in children and adolescents with autism and conduct disorder. Journal of Clinical Psychiatry, 64, 16–25.PubMed

McTighe, S. M., Neal, S. J., Lin, Q., Hughes, Z. A., & Smith, D. G. (2013). The BTBR mouse model of autism spectrum disorders has learning and attentional impairments and alterations in acetylcholine and kynurenic acid in prefrontal cortex. PLoS ONE,. doi:10.1371/journal.pone.0062189.PubMedCentralPubMed

Mikhail, F. M., Lose, E. J., Robin, N. H., Descartes, M. D., Rutledge, K. D., Rutledge, S. L., et al. (2011). Clinically relevant single gene or intragenic deletions encompassing critical neurodevelopmental genes in patients with developmental delay, mental retardation, and/or autism spectrum disorders. American Journal of Medical Genetics, Part A, 155, 2386–2396. doi:10.1002/ajmg.a.34177.CrossRef

Murray, R. P., Bailey, W. C., Daniels, K., Bjornson, W. M., Kurnow, K., Connett, J. E., et al. (1996). Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Chest, 109, 438–445. doi:10.1378/chest.109.2.438.CrossRefPubMed

Newhouse, P., Kellar, K., Aisen, P., White, H., Wesnes, K., Coderre, E., et al. (2012). Nicotine treatment of mild cognitive impairment: A 6-month double-blind pilot clinical trial. Neurology, 78, 91–101. doi:10.1212/WNL.0b013e31823efcbb.PubMedCentralCrossRefPubMed

Perry, E. K., Lee, M. L., Martin-Ruiz, C. M., Court, J. A., Volsen, S. G., Merrit, J., et al. (2001). Cholinergic activity in autism: Abnormalities in the cerebral cortex and basal forebrain. The American Journal of Psychiatry, 158(7), 1058–1066.CrossRefPubMed

Picciotto, M. R., Higley, M. J., & Mineur, Y. S. (2012). Acetylcholine as a neuromodulator: Cholinergic signaling shapes nervous system function and behavior. Neuron, 76(1), 116–129. doi:10.1016/j.neuron.2012.08.036.PubMedCentralCrossRefPubMed

Rodgers, R. J. (1979). Effects of nicotine, mecamylamine, and hexamethonium on shock-induced fighting, pain reactivity, and locomotor behaviour in rats. Psychopharmacology (Berl), 66(1), 93–98.CrossRef

Rosin, R. A., Levine, M. D., & Peskind, E. (2001). Transdermal nicotine for agitation in dementia. The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry, 9(4), 443–444. doi:10.1176/appi.ajgp.9.4.443.CrossRef

Srivastava, E. D., Russell, M. A., Feyerabend, C., Masterson, J. G., & Rhodes, J. (1991). Sensitivity and tolerance to nicotine in smokers and nonsmokers. Psychopharmacology (Berl), 105, 63–68. doi:10.1007/BF02316865.CrossRef

Stigler, K. A., & McDougle, C. J. (2008). Pharmacotherapy of irritability in pervasive developmental disorders. Child and Adolescent Psychiatric Clinics of North America, 17(4), 739–752. doi:10.1016/j.chc.2008.06.002.CrossRefPubMed

Snaedal, J., Johannesson, T., Jonsson, J. E., & Gylfadottir, G. (1996). The effects of nicotine in dermal plaster on cognitive functions in patients with Alzheimer’s disease. Dementia (Basel, Switzerland) 7: 47–52.

Waldbillig, R. J. (1980). Suppressive effects of intraperitoneal and intraventricular injections of nicotine on muricide and shock-induced attack on conspecifics. Pharmacology, Biochemistry and Behavior, 12(4), 619–623.CrossRefPubMed

West, R., Hajek, P., Foulds, J., Nilsson, F., May, S., & Meadows, A. (2000). A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berl), 149, 198–202. doi:10.1007/s002130000382.CrossRef

White, H. K., & Levin, E. D. (1999). Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer’s disease. Psychopharmacology (Berl), 143, 158–165. doi:10.1007/s002130050931.CrossRef

White, H. K., & Levin, E. D. (2004). Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment. Psychopharmacology (Berl), 171, 465–471. doi:10.1007/s00213-003-1614-8.CrossRef

Yasui, D. H., Scoles, H. A., Horike, S.-I., Meguro-Horike, M., Dunaway, K. W., Schroeder, D. I., & Lasalle, J. M. (2011). 15q11.2-13.3 chromatin analysis reveals epigenetic regulation of CHRNA7 with deficiencies in Rett and autism brain. Human Molecular Genetics, 20(22), 4311–4323. doi:10.1093/hmg/ddr357.PubMedCentralCrossRefPubMed

Titel: Reduction of Aggressive Episodes After Repeated Transdermal Nicotine Administration in a Hospitalized Adolescent with Autism Spectrum Disorder
Auteurs: Gerrit I. Van Schalkwyk
Alan S. Lewis
Zheala Qayyum
Kourtney Koslosky
Marina R. Picciotto
Fred R. Volkmar
Publicatiedatum: 16-05-2015
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 9/2015
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-015-2471-0

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 9/2015

Brief Report: Use of Superheroes Social Skills to Promote Accurate Social Skill Use in Children with Autism Spectrum Disorder

An Evaluation of the Quality of Research on Evidence-Based Practices for Daily Living Skills for Individuals with Autism Spectrum Disorder

Brainstem White Matter Predicts Individual Differences in Manual Motor Difficulties and Symptom Severity in Autism

Examination of the Korean Modified Checklist of Autism in Toddlers: Item Response Theory

Making Inferences: Comprehension of Physical Causality, Intentionality, and Emotions in Discourse by High-Functioning Older Children, Adolescents, and Adults with Autism

Activity Participation and Sensory Features Among Children with Autism Spectrum Disorders